SCHEMBL16756381

SCHEMBL16756381

Cc1cc(-c2ccc3nc(C)n(Cc4ccccc4OC(F)F)c3c2)c[nH]c1=O

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 7/20 0.45
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
NPC1 O15118 1/20 0.39
GALR3 O60755 1/20 0.39
NR2F2 P24468 1/20 0.39
RAB9A P51151 1/20 0.39
PPARD Q03181 2/20 0.36
PPARA Q07869 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TNF P01375 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
USP2 O75604 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16756351 0.89 MEN1 (0.48) BRD4MEN1KMT2ANPC1GALR3
SCHEMBL15560797 0.79 GRIN1 (0.41) NPC1GALR3NR2F2RAB9APPARD
SCHEMBL18918983 0.79 MEN1 (0.43) MEN1KMT2ANPC1GALR3NR2F2
SCHEMBL16756414 0.79 MEN1 (0.43) MEN1KMT2ANPC1GALR3NR2F2
SCHEMBL16756580 0.79 TLR7 (0.44) NPC1GALR3NR2F2RAB9APPARD
SCHEMBL16756574 0.78 BRD4 (0.40) BRD4NPC1GALR3NR2F2RAB9A
SCHEMBL15560205 0.78 GRIN1 (0.47) NPC1GALR3NR2F2RAB9APPARD
SCHEMBL16756558 0.78 GALR3 (0.43) NPC1GALR3NR2F2RAB9AKDM4E
SCHEMBL16756407 0.78 HPGD (0.44) BRD4MEN1KMT2AGALR3NR2F2
SCHEMBL15552701 0.77 GALR3 (0.46) MEN1KMT2ANPC1GALR3NR2F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858983-B1 TNF-ALPHA MODULATING BENZIMIDAZOLES UCB BIOPHARMA SPRL (BE) 2018-04-18 EP disclosed
US-9550737-B2 TNF -α modulating benzimidazoles UCB BIOPHARMA SPRL (BE) 2017-01-24 US disclosed
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles UCB BIOPHARMA SPRL (BE) 2015-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles TNF, TNFRSF1A, NFKBIA BRD4 976/4885MEN1 3836/4885KMT2A 3732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.